Experimental cocktail aims to revive immune attack on Hard-to-Treat cancers
NCT ID NCT03228667
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 30 times
Summary
This study tests a combination of an experimental immune booster (N-803) with standard checkpoint inhibitors in people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease progressed after prior immunotherapy. The goal is to see if the combo can shrink tumors and improve survival. About 40 participants will receive the drugs by injection or IV every few weeks, and researchers will monitor safety and immune responses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Alaska Clinical Research Center
Anchorage, Alaska, 99530, United States
-
Baptist Health - Lexington
Lexington, Kentucky, 40503, United States
-
Baptist Health- Louisville
Louisville, Kentucky, 40207, United States
-
Bon Secours Richmond
Richmond, Virginia, 23114, United States
-
Chan Soon-Shiong Institute for Medicine
El Segundo, California, 90245, United States
-
Cleveland Clinic - Main Site
Cleveland, Ohio, 44195, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756, United States
-
Desert Hematology Oncology Medical Group, Inc.
Rancho Mirage, California, 92270, United States
-
Genesis Cancer Center
Hot Springs, Arkansas, 71913, United States
-
Gettysburg/Hanover Cancer Centers
Gettysburg, Pennsylvania, 17325, United States
-
Glendale Adventist Medical Center
Glendale, California, 91206, United States
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Horizon Oncology Associates
Lafayette, Indiana, 47905, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Memorial Healthcare System
Hollywood, Florida, 33021, United States
-
MemorialCare Health System
Fountain Valley, California, 37846, United States
-
Mercy Clinic Cancer & Hematology - Chub O'Reilly Cancer Center
Springfield, Missouri, 65804, United States
-
Mercy Clinic Oklahoma City
Oklahoma City, Oklahoma, 73120, United States
-
Mercy Research Joplin
Joplin, Missouri, 64804, United States
-
Miami Cancer Institute (Baptist Health South Florida)
Miami, Florida, 33176, United States
-
Oncology Consultants of Houston
Houston, Texas, 77024, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
Sanford Clinical Research
Sioux Falls, South Dakota, 57104, United States
-
Spartanburg Medical Center
Spartanburg, South Carolina, 29303, United States
-
St. Francis Cancer Center/Bon Secours St. Francis Health System
Greenville, South Carolina, 29607, United States
-
St. Vincent Frontier Cancer Center (SCL)
Billings, Montana, 59102, United States
-
University of Iowa Holden Comprehensive Cancer Center
Iowa City, Iowa, 52242, United States
-
University of Miami
Miami, Florida, 33180, United States
-
University of Minnesota - Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
-
University of Rochester
Rochester, New York, 14642, United States
-
University of Southern California Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Tennessee Medical Center
Knoxville, Tennessee, 37920, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
N-803 (nogapendekin alfa inbakicept) plus a checkpoint inhibitor (pembrolizumab, nivolumab, or atezolizumab)
What this could lead to
If successful, this combination could offer a new treatment option for patients whose cancers have stopped responding to standard immunotherapy, potentially shrinking tumors and extending survival.
What could go wrong
This is an early-phase (2b) trial with only 40 participants across many cancer types, so results may not apply broadly. The added drug N-803 may cause side effects like infusion reactions or immune-related inflammation, and the combination may not work better than existing therapies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.